Skip to main content
. Author manuscript; available in PMC: 2017 Mar 17.
Published in final edited form as: Circulation. 2011 Jul 5;124(3):335–345. doi: 10.1161/CIRCULATIONAHA.110.985150

Table 1. Demographic Characteristics and Clinical Details of the Participants.

Study 2
Study 1 Placebo Atorvastatin Study 3
Patients (M/F), n   492 (411/81)   21 (20/1)  21 (18/3)*  26 (21/5)
Risk factors
    Age, y     65.9±0.41   67.38±1.99 66.14±2.04*     63.5±1.4
    Diabetes mellitus, n          159           9          7*           7
    Dyslipidemia, n          311           0          0           9
    Hypertension, n          333          16         18*         12
    Smokers, n
        Current          185            7           8*           7
        Ex-smokers          212          10           9*         13
    Body mass index, kg/m2     27.7±0.22     27.7±0.8     27.5±0.7*     27.9±0.7
Serum lipid levels
    Total cholesterol, mg/dL
        Baseline   166 (143–195)   205 (157–244)   225 (184–243)   184 (141–218)
        Posttreatment           …   191 (165–251)   171 (144–204)           …
    Triglycerides, mg/dL
        Baseline   125 (94–162)   206 (102–264)   132 (94–191)   123 (104–160)
        Posttreatment           …   146 (105–185)   113 (89–166)           …
HDL, mg/dL
    Baseline 39.0 (33.0–43.8) 35.0 (31.0–47.0) 39.0 (35.5–42.8) 35.0 (31.5–40.0)
    Posttreatment          … 39.0 (32.5–42.0) 37.0 (33.0–45.0)          …
Medication, n
    Statins          395          …          ….              9
    ACEi          272            8         11*            16
    ARBs            52            4           6*              5
    CCBs          135            5           5*              4
    β-blockers          368          13         13*            21
    Aspirin          390          12         13*            22
    Clopidogrel          154            8           6*            14
    Diuretics          104            8         10*              6

HDL indicates high-density lipoprotein; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; and CCB, calcium channel blockers. There was no significant difference in the changes of serum lipid levels between the atorvastatin- and placebo-treated groups (as tested by ANOVA for repeated measures with time-by-treatment interaction). Continuous variables are expressed as mean±SEM or median (25th to 75th percentile) as appropriate.

*

P=NS (P>0.05 vs placebo).